SERPING1 Protein (His Tag)

Plasma Protease C1 Inhibitor ( SERPING1 / C1IN ) Protein

SERPING1 / C1IN Protein Price Inquiry ( Available Sizes )

≥1mg Bulk:  Inquiring Price

SERPING1 / C1IN Protein Product Information

• Synonym: C1IN, C1INH, C1NH, HAE1, HAE2, SERPING1
• Protein Construction: A DNA sequence encoding the human SERPING1 (NP_000053.2) precursor (Met 1-Ala 500) was expressed with a polyhistidine tag at the C-terminus.
• Source: Human
• Expression Host: Human Cells

SERPING1 / C1IN Protein QC Testing

• Purity: > 95 % as determined by SDS-PAGE.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Asn 23
• Molecular Mass: The secreted recombinant human SERPING1 consists of 489 amino acids and predictes a molecular mass of 54.3 kDa. In SDS-PAGE under reducing conditions, it migrates with the apparent molecular mass of 110 kDa due to glycosylation.
• Formulation: Lyophilized from sterile PBS, pH 7.4
• SDS-PAGE: SERPING1 protein

SERPING1 / C1IN Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SERPING1 / C1IN Protein Description

Plasma protease C1 inhibitor, also known as C1-inhibiting factor, C1-INH, C1 esterase inhibitor, SERPING1 and C1IN, is a serine protease inhibitor protein. C1-INH is the largest member among the serpin class of proteins. Remarkably, C1-INH has a 2-domain structure, unlike most family members. The C-terminal serpin domain is similar to other serpins, and this part of C1-INH provides the inhibitory activity. The N-terminal domain is not essential for C1-INH to inhibit proteinases and has no similarity to other proteins. The main function of C1-INH is the inhibition of the complement system to prevent spontaneous activation. C1-INH is an acute phase protein and circulates in blood at levels of around 0.25 g/L, whose levels rise 2-fold during inflammation. C1-INH irreversibly binds to and inactivates C1r and C1s proteinases in the C1 complex of classical pathway of complement. C1-INH prevents the proteolytic cleavage of later complement components C4 and C2 by C1 and MBL. Although named after its complement inhibitory activity, C1-INH also inhibits proteinases of the fibrinolytic, clotting, and kinin pathways. Most notably, C1-INH is the most important physiological inhibitor of plasma kallikrein, fXIa and fXIIa.

References

1. Theriault, A. et al., 1990, Hum. Genet. 84 (5): 477-9. 
2. Davis, AE. et al., 2004, Drug News Perspect. 17 (7): 439-46. 
3. Koles, K. et al., 2004, Glycobiology. 14 (1): 51-64. 
4. Cicardi, M. et al., 2005, Springer Semin. Immunopathol. 27(3): 286-98. 
5. Bernstein, JA. et al., 2008, Ann. Allergy Asthma Immunol.100: S41-6.